Lessons from the 2023 Launch Class White Paper

This white paper presents an analysis of the performance of the 2023 launch class in comparison to previous years, specifically focusing on product launches in the U.S. from January 2020 to December 2023. It highlights that 50% of the launches underperformed their first-year forecasts, while 39% overperformed, indicating an improvement from prior years. The paper details the factors contributing to the success of these launches, including the importance of launch experience and addressing unmet medical needs. Notable examples of successful products include RSV vaccines and treatments for rare diseases, which exceeded sales forecasts due to strong clinical value and effective market strategies. The document also discusses the role of established companies in achieving early success and the significance of patient access initiatives. Through various case studies, the paper outlines how companies leveraged their expertise and market insights to navigate challenges and achieve commercial success in a competitive landscape.